1. Home
  2. UTL vs SGMT Comparison

UTL vs SGMT Comparison

Compare UTL & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UNITIL Corporation

UTL

UNITIL Corporation

SELL

Current Price

$55.65

Market Cap

944.1M

Sector

Utilities

ML Signal

SELL

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

SELL

Current Price

$10.17

Market Cap

761.6M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
UTL
SGMT
Founded
1984
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Power Generation
Sector
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
944.1M
761.6M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
UTL
SGMT
Price
$55.65
$10.17
Analyst Decision
Hold
Buy
Analyst Count
3
12
Target Price
★ $54.33
$27.27
AVG Volume (30 Days)
84.9K
★ 1.1M
Earning Date
11-02-2026
11-12-2026
Dividend Yield
★ 3.41%
N/A
EPS Growth
★ 1.37
N/A
EPS
★ 2.02
N/A
Revenue
★ $536,000,000.00
$2,000,000.00
Revenue This Year
$15.56
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$27.59
★ N/A
Revenue Growth
★ 8.33
N/A
52 Week Low
$47.18
$4.50
52 Week High
$58.33
$11.45

Technical Indicators

Market Signals
Indicator
UTL
SGMT
Relative Strength Index (RSI) 56.93 51.36
Support Level $50.41 $9.95
Resistance Level $57.80 $11.23
Average True Range (ATR) 1.15 0.68
MACD -0.10 0.05
Stochastic Oscillator 37.67 47.52

Price Performance

Historical Comparison
UTL
SGMT

About UTL UNITIL Corporation

Unitil Corp through its subsidiaries engages in the distribution of electricity and natural gas in its service territories in the states of New Hampshire, Massachusetts and Maine. Its natural gas operations include gas distribution utility operations and interstate gas transmission pipeline operations. It also engages in interstate natural gas transmission pipeline company, operating approximately 85 miles of underground gas transmission pipeline located in Maine and New Hampshire. The company's segments include Electric and Gas.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: